MedTrace Logo

Chlorhexidine Gluconate-gel Dressing for Exit Site Infection in Peritoneal Dialysis

NCT06022835 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-09-05

No results posted yet for this study

Summary

Exit site infection (ESI) is one of the major predisposing factors to peritoneal dialysis (PD) related peritonitis. Chlorhexidine Gluconate (CHG) has been widely used for cutaneous disinfection for half a century. TegadermTM CHG is a water-proof dressing with gel pads that provide 2% CHG to the skin surface and effectively prevents catheter-related infections for intravascular catheters. However, its use has not been accessed in patients with PD catheters. We aim to evaluate the effectiveness of TegadermTM CHG dressing in preventing ESI in PD patients.

Conditions

  • Peritoneal Dialysis Catheter Exit Site Infection
  • End Stage Renal Disease on Dialysis
  • Dialysis; Complications

Interventions

OTHER

Chlorhexidine Gluconate-gel (CHG) Dressing

Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.

Sponsors & Collaborators

  • National Healthcare Group, Singapore

    lead OTHER_GOV

Principal Investigators

  • Allen Yan Lun Liu · Khoo Teck Puat Hospital, Singapore

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-27
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06022835 on ClinicalTrials.gov